These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29540495)

  • 1. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
    Boyer A; Pasquier E; Tomasini P; Ciccolini J; Greillier L; Andre N; Barlesi F; Mascaux C
    Eur Respir Rev; 2018 Mar; 27(147):. PubMed ID: 29540495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.
    Kulkarni NS; Gupta V
    Life Sci; 2022 Sep; 304():120716. PubMed ID: 35709894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of action.
    Parvathaneni V; Chilamakuri R; Kulkarni NS; Wang X; Agarwal S; Gupta V
    Life Sci; 2022 Oct; 306():120843. PubMed ID: 35908620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
    Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
    Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can independent research for mesothelioma achieve to treat this orphan disease?
    Guazzelli A; Meysami P; Bakker E; Bonanni E; Demonacos C; Krstic-Demonacos M; Mutti L
    Expert Opin Investig Drugs; 2019 Aug; 28(8):719-732. PubMed ID: 31262194
    [No Abstract]   [Full Text] [Related]  

  • 11. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
    Christoph DC; Eberhardt WE
    Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Maio M; Scherpereel A; Calabrò L; Aerts J; Perez SC; Bearz A; Nackaerts K; Fennell DA; Kowalski D; Tsao AS; Taylor P; Grosso F; Antonia SJ; Nowak AK; Taboada M; Puglisi M; Stockman PK; Kindler HL
    Lancet Oncol; 2017 Sep; 18(9):1261-1273. PubMed ID: 28729154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine deprivation for ASS1-deficient mesothelioma.
    Burki TK
    Lancet Oncol; 2016 Oct; 17(10):e423. PubMed ID: 27622996
    [No Abstract]   [Full Text] [Related]  

  • 18. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.